Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire worldwide rights of The Medicines Company to Kengreal® (cangrelor) and Cleviprex® (clevidipine), as well as rights to Argatroban for Injection, 50 mg per 50 mL. All three products are cardiovascular products for use in the hospital setting and all three are approved for sale in the U.S.
"Chiesi Group is fully committed to the continued success of our U.S. affiliate, and we will continue to provide support for the acquisition of marketed products that fit our profile, as well as ongoing investment in research and development," said Ugo DiFrancesco, CEO of Chiesi Farmaceutici S.p.A., Chiesi USA's parent company.
"Chiesi has an 80-plus year history of securing our future by investing in the well-being of patients who need us," DiFrancesco said, "and the U.S. is a significant contributor to our vision for that bright future."
Ken McBean, President and Chief Executive Officer of Chiesi USA said, "The acquisition of all three products is a strategic fit for us, as we expand our product portfolio to become a recognized leader in the hospital and adjacent specialties. We are committed to delivering products that meet the needs of providers and enhance care for patients in those settings."
The transaction is expected to close in the third quarter of 2016 and is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act.